Background
==========

Osteoarthritis (OA) is a disease characterized by the breakdown of articular cartilage and the formation of osteophytes. However, it has been gradually realized that OA is not merely an articular cartilage disease, but a disease of the whole joint \[[@B1],[@B2]\]. OA synovial membrane and subchondral bone have drawn considerably attention recently. Aberrant gene expression in OA synovium, OA fibroblast-like synoviocytes (FLS) and OA subchondral bone has been detected \[[@B3]-[@B6]\]. These findings suggest that OA synoviocytes and subchondral bone cells may be involved in the disease process of OA.

Few studies have investigated the potential role of OA meniscal cells in the disease process of OA. The knee menisci are specialized tissues that play a vital role in load transmission, shock absorption and joint stability. Knee menisci may absorb most of the shock generated at the joint because their combined mass is greater than that of the articular cartilage. The current dogma is that menisci protect the articular cartilage, but play a minimal role in the disease process of OA unless they are injured. However, increasing evidence suggests that knee menisci may not be passive bystanders in the disease process of OA. It has been reported that meniscal degeneration is a feature of OA knee joints as revealed by magnetic resonance imaging \[[@B7],[@B8]\]. There is a strong association between meniscal damage/degenerative tears and cartilage loss \[[@B9]\]. In addition, it has been found that meniscal degeneration contributes to joint space narrowing \[[@B10]\]. Taken together, these findings and observations suggest that pathological changes and extracellular matrix degeneration also occur in OA menisci. OA menisci, similar to OA synovial membrane and OA subchondral bone, may play an active role in the disease process of OA.

In the present study, we examined the prevalence of meniscal degeneration in OA patients who underwent joint replacement surgery, and analyzed the correlation between the degeneration of menisci and the degeneration of articular cartilage. We also examined differential gene expression between OA meniscal cells and normal meniscal cells to test the hypothesis that OA meniscal cells are different from normal meniscal cells and may display a disease-specific gene expression profile. The determination of the differential gene expression between OA and normal meniscal cells may not only provide experimental evident to support our hypothesis, but also may reveal new therapeutic targets for OA therapy and uncover novel disease markers for early diagnosis of OA.

Methods
=======

Menisci and articular cartilage specimens
-----------------------------------------

Menisci and articular cartilage specimens were collected from OA patients who underwent joint replacement surgery and from osteosarcoma patients who underwent lower limb amputation surgery with the approval of the authors\' Institutional Review Board. The need for informed consent was waived since the menisci and articular cartilage were surgical waste of routine joint replacement surgery and lower limb amputation surgery, and there was no patient private information being collected. Specimens were transported to the laboratory from the operation room at our hospital in sterile tissue culture medium. The medial menisci and the medial articular cartilage of the tibia were graded (by DRM, PRH and YS) according to following scales. For the medial meniscus: 0 = normal appearing surface; 1 = minimal fibrillation and degeneration; 2 = moderate fibrillation and degeneration; 3 = severe fibrillation and degeneration, no tears; 4 = severe fibrillation and degeneration, multiple incomplete tears, or complete tears. For medial articular cartilage of the tibia: 0 = normal-appearing surface; 1 = minimal fibrillation and degeneration; 2 = erosion extending to middle layers; 3 = erosion extending into the deep layers; 4 = erosion extending to the subchondral bone, and 5 = the majority of articular cartilage completely absent.

Preparation and culture of meniscal cells
-----------------------------------------

Dulbecco\'s modified eagle medium, fetal bovine serum, stock antibiotic and antimycotic mixture were products of Invitrogen (Carlsbad, CA). Meniscal cells were isolated from meniscal specimens as previously described \[[@B11]\]. Briefly, when meniscal specimens were arrived in sterile tissue culture medium, the central region of the medial meniscus was incised, and processed to remove fatty and synovial tissues. These meniscal specimens were then minced into small pieces (3 mm × 3 mm), and cultured in 100 mm plates at 37°C in medium containing 0.5% antibiotic/antimycotic solution and 10% serum. Every three days, medium was changed. Meniscal cells proliferated, migrated out the tissues, attached to the plate and expanded. When meniscal cells reached 80% confluence, they were replated and expanded in monolayer culture. Passage two cells were used in all studies. Meniscal cells prepared from meniscal specimens derived from osteosarcoma patients were used as normal control meniscal cells.

RNA extraction and microarrays
------------------------------

OA meniscal cells and normal meniscal cells (passage 2) were plated in 100 mm plates at 75% confluence. On the second day, medium containing 1% serum was added and cells were cultured for twenty-four hours. Medium (1% serum) was changed again and cells cultured for another twenty-four hours. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA), and purified using Oligotex kit (Qiagen, Valencia, CA). Microarray analyses were performed using these RNA samples. For microarray analysis, double stranded DNA was synthesized from RNA samples using SuperScript double-stranded cDNA synthesis kit (Invitrogen, Carlsbad, CA). The DNA product was purified using GeneChip sample cleanup module (Affymetrix, Santa Clara, CA). cRNA was synthesized and biotin labeled using BioArray high yield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY). The product was purified using GeneChip sample cleanup module and subsequently chemically fragmented. The fragmented, biotinylated cRNA was hybridized to HG-U133_Plus_2 gene chip (Affymetrix, Santa Clara, CA) using Affymetrix Fluidics Station 400. The fluorescent signal was quantified during two scans by Agilent Gene Array Scanner G2500A (Agilent Technologies, Palo Alto, CA), and GeneChip operating Software (Affymetrix, Santa Clara, CA).

Real-time RT-PCR
----------------

cDNA was synthesized using TaqMan^®^Reverse Transcription Reagents (Applied Biosystems, Inc., University Park, IL). Quantification of relative transcript levels for selected genes and the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using the ABI7000 Real Time PCR system (Applied Biosystems, Inc., University Park, IL). TaqMan^®^Gene Expression assays were used, which contains a FAM-MGB probe for fluorescent detection. cDNA samples were amplified with an initial Taq DNA polymerase activation step at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing at 60°C for one minute. For each gene, Ct values were obtained in triplicates. Fold change was calculated \[[@B12]\] and the expression level of the genes of interest was normalized to *GAPDH*. Each real time RT-PCR experiment was repeated twice in triplicate.

Statistical Analysis
--------------------

The Spearman\'s correlations between the grades of meniscal degeneration and the grades of articular cartilage degeneration were calculated with SAS^®^software (version 9.1). A two-tailed p-value of \< 0.05 was considered statistically significant. For microarray analysis, Genesifter software (VizX Labs, Seattle, WA) was used to determine fold changes in gene expression, and gene ontologies. Statistical significance was determined using the Student t-test (p \< 0.05). A correction factor for false discovery rate was applied using the Benjamini and Hochberg method \[[@B13]\].

Results
=======

Degeneration of menisci in OA patients
--------------------------------------

Demographic patient features and assigned grades are presented in Table [1](#T1){ref-type="table"}. All menisci had signs of degeneration. More than 80% menisci showed signs of severe degeneration (grade 4 or grade 3). Representative images of grade 4 OA menisci and grade 0 normal control menisci are shown in Figure [1](#F1){ref-type="fig"}. Grade 4 OA menisci displayed discolorations and an extremely rough surface. Severe degeneration and fissures/tears were apparent. In contrast, grade 0 control menisci displayed a smooth, white and glistening surface, with no any signs of degeneration.

###### 

Demographic data and grades of articular cartilage and menisci\*

  I        Cartilage Grade      \# Subjects       Mean Age ± SD
  -------- -------------------- ----------------- -------------------
           0                    1 F               39
                                                  
           0                    1 F               12
                                                  
           0                    1 M               43
                                                  
           2                    3 F, 1 M          62 ± 13
                                                  
           3                    6 F, 5 M          64 ± 9
                                                  
           4                    15 F, 4 M         62 ± 11
                                                  
           5                    12 F, 5 M         67 ± 9
                                                  
  **II**   **Meniscus Grade**   **\# Subjects**   **Mean Age ± SD**
                                                  
           0                    1 F               39
                                                  
           0                    1 F               12
                                                  
           0                    1 M               43
                                                  
           2                    4 F, 3 M          57 ± 12
                                                  
           3                    12 F, 6 M         64 ± 9
                                                  
           4                    20 F, 6 M         66 ± 9

\*The first three patients are osteosarcoma patients. The rest fifty-one patients are OA patients. F, female; M, male

![**Representative photos of normal control menisci and OA menisci**. Control menisci (left, top to bottom) were obtained from a 39 year old female osteosarcoma patient, a 43 year old male osteosarcoma patient and a 12 year old female osteosarcoma patient underwent lower limb amputation surgery. OA menisci (right, top to bottom) were obtained from a 65 year old female OA patient, a 67 year old female OA patient and a 50 year old female OA patient.](1471-2474-11-19-1){#F1}

The relationship between the grade of menisci and the grade of articular cartilage was examined. A correlation between the grade of menisci and the grade of articular cartilage was found. The Spearman\'s correlation coefficient (r) was 0.672 (p \< 0.0001). Of the seventeen OA patients who had grade 5 (the highest grade of articular cartilage degeneration) articular cartilage, fourteen patients (82%) had grade 4 medial meniscus (the highest grade of meniscal degeneration) and three patients had grade 3 medial meniscus. Of the nineteen OA patients who had grade 4 articular cartilages, ten patients had grade 4 (58.82%) and seven had grade 3 (41.17%) medial meniscus. Only two patients had grade 2 (0.11%) medial meniscus.

Differential gene expression
----------------------------

Microarray analyses of the differential gene expression between OA meniscal cells prepared from menisci (grade 4) derived from five OA patients and normal meniscal cells prepared from menisci (grade 0) derived from three osteosarcoma patients were carried out as described in Methods. The row microarray data can be found in Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/projects/geo/>) with the accession number \#GSE19060. Table [2](#T2){ref-type="table"} presents the demographic data of the meniscal specimens which were the basis of this analysis. Of more than 50,000 transcripts examined, 505 transcripts that displayed differential gene expression (more than 1.2 fold) were identified; 149 transcripts were expressed at significantly higher levels and 356 transcripts at significantly lower levels in OA meniscal cells compared to normal meniscal cells. The differentially expressed genes were classified according to gene ontology category biological process using GeneSifter software (VizX Labs, Seattle, WA). Selected genes, which fell into specific biological processes previously implicated in OA or suspected to play a role in OA, or displayed a distinct expression pattern, are listed in Table [3](#T3){ref-type="table"}.

###### 

Demographic data and grades of menisci that were used to prepare meniscal cells\*

  Patients   Age/Gender/Diagnosis   Grade Meniscus
  ---------- ---------------------- ----------------
  A          39/F (osteosarcoma)    0
                                    
  B          43/M (osteosarcoma)    0
                                    
  C          12/F (osteosarcoma)    0
                                    
  1          65/F (OA patient)      4
                                    
  2          56/F (OA patient)      4
                                    
  3          50/F (OA patient)      4
                                    
  4          52/F (OA patient)      4
                                    
  5          61/M (OA patient)      4

\* F, female; M, male; OA, osteoarthritis

###### 

Genes differentially expressed in OA meniscal cells compared to normal meniscal cells.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biological process                    Gene Name   Gene ID                   Differ\    Description
                                                                              Exp\       
                                                                              (fold)\*   
  ------------------------------------- ----------- ------------------------- ---------- ---------------------------------------------------------------------------
  Immune response                                                                        

                                                                                         

                                        HLA-DPA1    M27487                    5.3        Major histocompatibility complex, class II, DP alpha 1

                                                                                         

                                        IFI6        [NM_022873](NM_022873)    2.0        Interferon, alpha-inducible protein 6

                                                                                         

                                        CFH         [X04697](X04697)          1.7        Complement factor H

                                                                                         

                                        CTSS        [NM_004079](NM_004079)    1.6        Cathepsin S

                                                                                         

                                        FYN         S74774                    1.5        FYN oncogene related to SRC, FGR, YES

                                                                                         

                                        ILF2        [NM_004515](NM_004515)    -1.3       Interleukin enhancer binding factor 2, 45 kDa

                                                                                         

                                        PSMB9       [AI375915](AI375915)      -1.2       Proteasome (prosome, macropain) subunit, beta type, 9

                                                                                         

  Inflammatory\                                                                          
  Response                                                                               

                                                                                         

                                        ITGB2       [NM_000211](NM_000211)    6.6        Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)

                                                                                         

                                        CFH         [X04697](X04697)          1.7        Complement factor H

                                                                                         

                                        BDKRB2      [NM_000623](NM_000623)    1.3        Bradykinin receptor B2

                                                                                         

  Cytokine production                                                                    

                                                                                         

                                        SRGN        [NM_002727](NM_002727)    2.8        Serglycin

                                                                                         

                                        ARNT        [AI768497](AI768497)      2.3        Aryl hydrocarbon receptor nuclear translocator

                                                                                         

                                        INHBA       [M13436](M13436)          1.9        Inhibin, beta A

                                                                                         

  Calcium ion transport                                                                  

                                                                                         

                                        CACNA1C     [F11066](F11066)          1.5        Calcium channel, voltage-dependent, L type, alpha 1C subunit

                                                                                         

                                        FYN         [S74774](S74774)          1.5        FYN oncogene related to SRC, FGR, YES

                                                                                         

                                        CHRNB2      [NM_000748](NM_000748)    1.4        Cholinergic receptor, nicotinic, beta 2 (neuronal)

                                                                                         

  Biomineral formation                                                                   

                                                                                         

                                        ENPP1       [BF057080](BF057080)      1.7        Ectonucleotide pyrophosphatase/phosphodiesterase 1

                                                                                         

                                        SRGN        [NM_002727](NM_002727)    2.8        Serglycin

                                                                                         

                                        ACVR2A      [AI149508](AI149508)      1.5        Activin A receptor, type IIA

                                                                                         

  Cell proliferation                                                                     

                                                                                         

                                        ITGB2       [NM_000211](NM_000211)    6.6        Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)

                                                                                         

                                        FGF7        [NM_002009](NM_002009)    4.1        Fibroblast growth factor 7 (keratinocyte growth factor)

                                                                                         

                                        ELN         [AA479278](AA479278)      2.5        Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome)

                                                                                         

                                        IGFBP7      [NM_001553](NM_001553)    2.4        Insulin-like growth factor binding protein 7

                                                                                         

                                        SKAP2       [AB014486](AB014486)      2.2        Src kinase associated phosphoprotein 2

                                                                                         

                                        ARNT        [AI768497](AI768497)      2.3        Aryl hydrocarbon receptor nuclear translocator

                                                                                         

                                        FOXO1       [NM_002015](NM_002015)    1.5        Forkhead box O1

                                                                                         

                                        BCAT1       [AL390172](AL390172)      1.5        Branched chain aminotransferase 1, cytosolic

                                                                                         

                                        ACVR2A      [AI149508](AI149508)      1.5        Activin A receptor, type IIA

                                                                                         

                                        TCF7L2      [AA664011](AA664011)      1.4        Transcription factor 7-like 2 (T-cell specific, HMG-box)

                                                                                         

                                        CHRNB2      [NM_000748](NM_000748)    1.4        Cholinergic receptor, nicotinic, beta 2 (neuronal)

                                                                                         

                                        TCFL5       [NM_006602](NM_006602)    1.2        Transcription factor-like 5 (basic helix-loop-helix)

                                                                                         

                                        NRP1        [AA609131](AA609131)      -1.3       Neuropilin 1

                                                                                         

                                        PHB         [AL560017](AL560017)      -1.3       Prohibitin

                                                                                         

                                        TBX5        [NM_000192](NM_000192)    -1.3       T-box 5

                                                                                         

                                        NCK2        [BC000103](BC000103)      -1.2       NCK adaptor protein 2

                                                                                         

                                        PRPF19      [NM_014502](NM_014502)    -1.2       PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae)

                                                                                         

  Integrin-mediated signaling pathway                                                    

                                                                                         

                                        ITGB2       [NM_000211](NM_000211)    6.6        Integrin, beta 2

                                                                                         

                                        ITGB8       [BF513121](BF513121)      3.6        Integrin, beta 8

                                                                                         

                                        ITGA11      [AF109681](AF109681)      1.5        integrin, alpha 11

                                                                                         

                                        GAB2        [NM_012296](NM_012296)    1.5        GRB2-associated binding protein 2

                                                                                         

  Skeletal system/Tissue development                                                     

                                                                                         

                                        DSP         [NM_004415](NM_004415)    5.2        Desmoplakin

                                                                                         

                                        FGF7        [NM_002009](NM_002009)    4.2        Fibroblast growth factor 7 (keratinocyte growth factor)

                                                                                         

                                        SRGN        [NM_002727](NM_002727)    2.8        Serglycin

                                                                                         

                                        INHBA       [M13436](M13436)          1.9        Inhibin, beta A

                                                                                         

                                        TIMP3       [AW338933](AW338933)      1.7        TIMP metallopeptidase inhibitor 3

                                                                                         

                                        ENPP1       [BF057080](BF057080)      1.7        Ectonucleotide pyrophosphatase/phosphodiesterase 1

                                                                                         

                                        COL5A1      [N30339](N30339)          1.7        Collagen, type V, alpha 1

                                                                                         

                                        ACVR2A      [AI149508](AI149508)      1.5        Activin A receptor, type IIA

                                                                                         

                                        FBN1        [AW955612](AW955612)      1.4        Fibrillin 1

                                                                                         

                                        BARX1       [NM_021570](NM_021570)N   -1.9       BARX homeobox 1

                                                                                         

                                        GABBR1      [NM_001470](NM_001470)    -1.9       Gamma-aminobutyric acid (GABA) B receptor, 1

                                                                                         

                                        HOXA11      [H94842](H94842)          -1.5       Homeobox A11

                                                                                         

                                        CHST11      [NM_018413](NM_018413)    -1.5       Carbohydrate (chondroitin 4) sulfotransferase 11

                                                                                         

                                        NSDHL       [BC000245](BC000245)      -1.4       NAD(P) dependent steroid dehydrogenase-like

                                                                                         

                                        ZNRD1       [AF230337](AF230337)      -1.3       Zinc ribbon domain containing 1

                                                                                         

                                        SMURF1      [AF199364](AF199364)      -1.3       SMAD specific E3 ubiquitin protein ligase 1

                                                                                         

  DNA repair                                                                             

                                                                                         

                                        ZSWIM7      [BE645222](BE645222)      -1.6       Zinc finger, SWIM-type containing 7

                                                                                         

                                        WDR33       [AB044749](AB044749)      -1.5       WD repeat domain 33

                                                                                         

                                        ASF1A       [NM_014034](NM_014034)    -1.5       ASF1 anti-silencing function 1 homolog A (S. cerevisiae)

                                                                                         

                                        ATM         [U82828](U82828)          -1.3       ataxia telangiectasia mutated

                                                                                         

                                        PMS2L1      [AI375694](AI375694)      -1.3       Postmeiotic segregation increased 2-like 1

                                                                                         

                                        ALKBH2      [AI865555](AI865555)      -1.2       AlkB, alkylation repair homolog 2 (E. coli)

                                                                                         

                                        XRCC6       [NM_001469](NM_001469)    -1.2       X-ray repair complementing defective repair in Chinese hamster cells 6

                                                                                         

                                        DCLRE1A     [D42045](D42045)          -1.2       DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae)

                                                                                         

                                        PRPF19      [NM_014502](NM_014502)    -1.2       PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae)

                                                                                         

                                        ELN         [AA479278](AA479278)      2.5        Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome)

                                                                                         

  Cellular biosynthetic process                                                          

                                                                                         

                                        PITX2       [NM_000325](NM_000325)    -6.4       Paired-like homeodomain 2

                                                                                         

                                        NR3C2       [NM_000901](NM_000901)    -5.8       Nuclear receptor subfamily 3, group C, member 2

                                                                                         

                                        GALNT6      [AW014155](AW014155)      -4.5       Polypeptide N-acetylgalactosaminyltransferase 6

                                                                                         

                                        RGMB        [BE855765](BE855765)      -2.7       RGM domain family, member B

                                                                                         

                                        FOXF2       [NM_001452](NM_001452)    -2.2       Forkhead box F2

                                                                                         

                                        ZNF529      [AL109722](AL109722)      -2.1       Zinc finger protein 529

                                                                                         

                                        BARX1       [NM_021570](NM_021570)    -1.9       BARX homeobox 1

                                                                                         

                                        DHODH       [M94065](M94065)          -1.9       Dihydroorotate dehydrogenase

                                                                                         

                                        LMO4        [BC003600](BC003600)      -1.8       LIM domain only 4

                                                                                         

                                        BRWD1       [NM_018963](NM_018963)    -1.7       Bromodomain and WD repeat domain containing 1

                                                                                         

                                        TARS2       [NM_025150](NM_025150)    -1.7       Threonyl-tRNA synthetase 2, mitochondrial (putative)

                                                                                         

                                        HLX         [M60721](M60721)          -1.7       H2.0-like homeobox

                                                                                         

                                        BNC2        [AI767962](AI767962)      -1.7       Basonuclin 2

                                                                                         

                                        PGD         [NM_002631](NM_002631)    -1.6       Phosphogluconate dehydrogenase

                                                                                         

                                        MEIS1       [AL832770](AL832770)      -1.6       Meis homeobox 1

                                                                                         

                                        ZNF420      [AI339586](AI339586)      -1.6       Zinc finger protein 420

                                                                                         

                                        ZFP28       [AA831323](AA831323)      -1.5       Zinc finger protein 28 homolog (mouse)

                                                                                         

                                        CARS2       [NM_024537](NM_024537)    -1.5       Cysteinyl-tRNA synthetase 2, mitochondrial (putative)

                                                                                         

                                        HOXA11      [H94842](H94842)          -1.5       Homeobox A11

                                                                                         

                                        PDLIM1      [BC000915](BC000915)      13.2       PDZ and LIM domain 1 (elfin)

                                                                                         

                                        ITGB2       [NM_000211](NM_000211)    6.6        Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)

                                                                                         

                                        LMCD1       [NM_014583](NM_014583)    3.5        LIM and cysteine-rich domains 1

                                                                                         

                                        KRT7        [BC002700](BC002700)      3.1        Keratin 7

                                                                                         

                                        ARNT        [AI768497](AI768497)      2.3        Aryl hydrocarbon receptor nuclear translocator

                                                                                         

                                        ZNF415      [NM_018355](NM_018355)    2.2        Zinc finger protein 415

                                                                                         

                                        ZNF630      [AK000580](AK000580)      2.0        Zinc finger protein 630

                                                                                         

                                        INHBA       [M13436](M13436)          1.9        Inhibin, beta A

                                                                                         

                                        GALNT1      [U41514](U41514)          1.7        Polypeptide N-acetylgalactosaminyltransferase 1

                                                                                         

                                        ENPP1       [BF057080](BF057080)      1.7        Ectonucleotide pyrophosphatase/phosphodiesterase 1

                                                                                         

  Miscellaneous                                                                          

                                                                                         

                                        PTGES       [AF010316](AF010316)      3.2        Prostaglandin E synthase

                                                                                         

                                        ADAMTS5     [NM_007038](NM_007038)    1.7        ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2)

                                                                                         

                                        DSP         [NM_004415](NM_004415)    5.2        Desmoplakin

                                                                                         

                                        FMOD        [NM_002023](NM_002023)    2.7        Fibromodulin

                                                                                         

                                        sFRP4       [AW089415](AW089415)      3.4        Secreted frizzled-related protein 4

                                                                                         

                                        MCAM        [M28882](M28882)          2.3        Melanoma cell adhesion molecule

                                                                                         

                                        TNXB        [NM_004381](NM_004381)    -1.3       Tenascin XB

                                                                                         

                                        FUS         [NM_004960](NM_004960)    -1.5       Fusion (involved in t(12;16) in malignant liposarcoma)

                                                                                         

                                        TBX5        [NM_000192](NM_000192)    -1.3       T-box 5
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Positive number indicates elevated expression (fold) in OA meniscal cells compared to normal meniscal cells. Negative number indicates decreased expression (fold) in OA meniscal cells compared to normal meniscal cells.

We were particularly interested in identifying distinct differential gene expression patterns. As shown in Table [3](#T3){ref-type="table"}, distinct differential gene expression patterns were apparent. For example, of the seven differentially-expressed genes classified in the immune response biological process, five genes had elevated expressions but only two genes had decreased expression in OA meniscal cells compared to the control meniscal cells. Of the three differentially-expressed genes classified in the inflammation response biological process, cytokine production biological process, calcium ion transport biological process or the biomineral formation biological process, all these genes had elevated expression in OA meniscal cells compared to the control meniscal cells. Of the four differentially-expressed genes classified in the regulation of phosphate metabolic process, three genes had elevated expression but only one gene had decreased expression in OA meniscal cells compared to the control meniscal cells. Of the eighteen genes classified in the cell proliferation biological process, thirteen genes had elevated expression but only five genes had decreased expression in OA meniscal cells compared to the control meniscal cells. Similar distinct expression patterns were also found in other categories of biological processes, including integrin-mediated signaling pathway and skeletal system/tissue development biological processes (Table [3](#T3){ref-type="table"}).

In contrast, most of the genes with decreased expressions in OA meniscal cells compared to the control meniscal cells fell into a different set of biological processes. For example, of the ten differentially-expressed genes classified in the DNA repair biological process, nine genes had decreased expression but only one gene had elevated expression in OA meniscal cells compare to the control meniscal cells. Of the ninety-one differentially expressed genes classified in the cellular biosynthetic process biological process, seventy-four genes had decreased expression in OA meniscal cells and only seventeen genes had elevated expression (Partial results are listed in Table [3](#T3){ref-type="table"}). These distinct distributions of the differentially-expressed genes in different sets of biological processes suggest that OA meniscal cells are different from normal meniscal cells. We also analyzed the differential gene expression between individual OA meniscal cells (OA1, OA2, OA3, OA4, and OA5) and the normal control meniscal cells together as a control group. Selected results are listed in Table [4](#T4){ref-type="table"}.

###### 

Genes differentially expressed in individual OA meniscal cells compared to normal meniscal cells.

  --------------------------------------------------------------------------------------------------------------------
  Gene\     Gene ID                  OA1    OA1    OA3    OA4    OA5    Description
  Name                                                                  
  --------- ------------------------ ------ ------ ------ ------ ------ ----------------------------------------------
  BST1      [NM_004334](NM_004334)   3.9    3.4    3.3    1.6    2.2    bone marrow stromal cell antigen 1

                                                                        

  FGF9      [NM_002010](NM_002010)   3.7    2.4    3.7    2.5    2.9    Fibroblast growth factor 9

                                                                        

  ACAN      [NM_013227](NM_013227)   2.4    1.6    1.6    0.0    1.6    Aggrecan

                                                                        

  COL11A1   [J04177](J04177)         0.0    11.5   5.8    2.2    3.6    Collagen, type XI, alpha 1

                                                                        

  ANKH      [AL833238](AL833238)     0.0    1.8    1.7    1.5    1.8    Ankylosis, progressive homolog (mouse)

                                                                        

  MGP       [NM_000900](NM_000900)   11.8   4.7    21.6   0.0    17.6   Matrix Gla protein

                                                                        

  TUFT1     [NM_020127](NM_020127)   2.8    2.7    1.9    0.0    0.0    Tuftelin 1

                                                                        

  TFIP11    [NM_012143](NM_012143)   2.2    1.6    0.0    0.0    0.0    Tuftelin interacting protein 11

                                                                        

  IL20RB    [AL578102](AL578102)     2.3    2.7    0.0    2.6    7.8    Interleukin 20 receptor beta

                                                                        

  IL26      [NM_018402](NM_018402)   1.7    1.6    1.6    0.0    3.0    Interleukin 26

                                                                        

  COL4A5    [AW052179](AW052179)     -3.1   -3.0   -3.1   -3.0   -3.1   Collagen, type IV, alpha 5 (Alport syndrome)

                                                                        

  MMP9      [NM_004994](NM_004994)   -2.2   -2.1   -2.1   0.0    -2.2   Matrix metallopeptidase 9

                                                                        

  MMP10     [NM_002425](NM_002425)   -2.7   -2.6   -2.7   -1.5   -2.6   Matrix metallopeptidase 10

                                                                        

  MMP12     [NM_002426](NM_002426)   -2.1   -2.0   -2.1   0.0    -2.1   Matrix metallopeptidase 12

                                                                        

  FZD10     [NM_007197](NM_007197)   -1.6   -1.5   -1.6   -1.5   -1.5   Frizzled homolog 10 (Drosophila)

                                                                        

  CYTL1     [NM_018659](NM_018659)   -2.6   -2.6   -2.6   -2.6   -2.5   Cytokine-like 1

                                                                        

  CHODL     [NM_024944](NM_024944)   -2.6   -2.6   -2.6          -2.6   Chondrolectin
  --------------------------------------------------------------------------------------------------------------------

\*Positive number indicates elevated expression (fold) in OA meniscal cells compared to normal meniscal cells. Negative number indicates decreased expression (fold) in OA meniscal cells compared to normal meniscal cells. 0.0 indicates there was no differential gene expression being detected.

Validation of differential expression of selected genes
-------------------------------------------------------

The genes selected for validation by quantitative real-time PCR included seven genes that displayed elevated expression in OA meniscal cells compared to normal meniscal cells (Table [5](#T5){ref-type="table"}). They were major histocompatibility complex, class II, DP alpha (*HLA-DPA1*), integrin, beta 2 (*ITGB2*), ectonucleotide phosphodiesterase 1 (*ENPP1*), ADAM metallopeptidase with thrombospondin type 1 motif 5 (*ADAMTS5*), prostaglandin E synthase (*PTGES*), etc. Matrix metalloproteinase 10 (*MMP10*), which displayed decreased expression in OA meniscal cells compared to normal meniscal cells, was also selected for validation. RNA sample extracted from OA1 meniscal cells (Table [4](#T4){ref-type="table"}) and RNA sample (mixture) extracted from the three normal control meniscal cells were used in the quantitative real time RT-PCR experiments. As shown in Table [5](#T5){ref-type="table"}, the differential expressions of these genes were confirmed.

###### 

Differential gene expression confirmed by real time RT-PCR\*

  Gene name   Gene ID                  Differential Expression\* Microarray   Differential Expression\* RT-PCR   Description
  ----------- ------------------------ -------------------------------------- ---------------------------------- -----------------------------------------------------------
  HLA-DPA1    [M27487](M27487)         5.3                                    10.5                               Major histocompatibility complex, class II, DP alpha
                                                                                                                 
  ITGB2       [NM_000211](NM_000211)   6.6                                    5.2                                Integrin, beta 2
                                                                                                                 
  PTGES       [AF010316](AF010316)     3.2                                    3.4                                Prostaglandin E synthase
                                                                                                                 
  ENPP1       [BF057080](BF057080)     1.7                                    2.1                                Ectonucleotide pyrophosphatase/phosphodiesterase 1
                                                                                                                 
  ADAMTS5     [BI254089](BI254089)     1.7                                    1.9                                ADAM metallopeptidase with thrombospondin type 1 motif, 5
                                                                                                                 
  IL26        [NM_018402](NM_018402)   1.7                                    4.3                                Interleukin 26
                                                                                                                 
  TUFT1       [NM_020127](NM_020127)   2.8                                    3.9                                Matrix metalloproteinase 1
                                                                                                                 
  MMP10       [NM_002425](NM_002425)   -2.7                                   -3.1                               Matrix metalloproteinase 10

\*Differential Expression \-- the numbers are the ratio of the relative expression level of a specific gene in OA1 meniscal cells to the relative expression level of the specific gene in the control meniscal cells (mixture of RNA prepared from the three normal control meniscal cells).

Discussion
==========

In the present study, we found that more than eighty five percent (85.7%) of the OA patients who underwent joint replacement surgery in our Medical Center had severe degenerative menisci (grades 4 or 3), indicating that meniscal degeneration is common in OA patients. We also found that meniscal degeneration correlated positively with articular cartilage degeneration in OA patients. The Spearman\'s correlation coefficient (r) was 0.672 (p \< 0.0001). Our finding is consistent with previous reports that meniscal degeneration/tears is a feature of OA knee joints \[[@B7]\], that meniscal degeneration contributes to joint space narrowing \[[@B10]\], that there is a strong association between meniscal damage and cartilage loss \[[@B9]\], and that degenerative meniscal tears are positively associated with the severity of articular degeneration compared with other types of meniscal tears \[[@B14]\]. Taken together, our findings suggest that meniscal degeneration in OA, similar to cartilage degeneration, is a major degenerative process regardless of whether it is primary or secondary. Further studies such as examination of the complete patient histories may provide information regarding the cause-result relationship between meniscal degeneration and cartilage degeneration.

If meniscal degeneration is a general feature of OA, one would like to assess whether OA meniscal cells are different from normal meniscal cells and may play a role in the development of OA. To this end, we examined the differential gene expression between OA meniscal cells and normal control meniscal cells. We have recently reported that numerous genes that were classified in the biological process of immune response displayed elevated expression in OA FLS compared to rheumatoid arthritis (RA) FLS. *HLA-DPA1*was expressed in OA FLS (hTERT-OA 13A FLS) 16 fold higher than that in RA FLS (hTERT-RA 516 FLS) \[[@B4]\]. Consistently, many genes that were classified in the biological process of immune response including *HLA-DPA1*also displayed elevated expression in OA meniscal cells (Table [3](#T3){ref-type="table"}). The findings indicate that OA meniscal cells, similar to OA FLS, may be involved in the inflammatory process observed in OA.

Calcium-containing crystals are found in the joint fluid of up to 65% of OA patients, and the presence of these crystals correlates with the radiographic evidence of cartilaginous degeneration \[[@B15]-[@B18]\]. There is evidence indicating that crystals may promote joint degeneration \[[@B19]-[@B21]\]. Most recently, it was demonstrated that the inhibition of meniscal calcification by calcium phosphocitrate, a potent anti-calcification agent, was accompanied by a significant reduction in the degeneration of articular cartilage in Hartley guinea pigs \[[@B22]\]. These data suggest that excessive meniscal calcification may play a role in OA. However, there have been no studies to investigate the alterations in OA meniscal cells or to identify the candidate disease genes that are potentially responsible for the excessive meniscal calcification in OA. In the present study, we found that many genes which are involved in biomineral formation such as *ENPP1*\[[@B23]\], in phosphate metabolic process such as *ITGB2*and in calcium ion transport such as calcium channel, voltage-dependent, L type, alpha 1C subunit (*CACNA1C*) are expressed at an elevated levels in OA meniscal cells compared to normal meniscal cells. These findings are consistent with clinical observations that meniscal calcification is more severe in OA menisci \[[@B24],[@B25]\] and that calcium content in OA menisci is positively correlated with the stage of meniscal degeneration \[[@B26]\]. In addition to the genes listed in Table [3](#T3){ref-type="table"}, several other genes that have been previously implicated in pathological calcification were also detected (Table [4](#T4){ref-type="table"}). They were ankylosis progressive homolog (*ANKH*) \[[@B27],[@B28]\], matrix Gla protein (*MGP*) \[[@B29],[@B30]\] and tuftelin (*TUFT1*) \[[@B31]-[@B33]\]. Taken together, our findings suggest that OA meniscal cells may be actively involved in the meniscal calcification process in OA.

Many genes that have been previously found to be expressed at elevated levels in other types of OA cells or tissues such as in OA articular cartilage and OA bone were also detected in this study. They were integrin, beta 8 (*ITGB8*) \[[@B34]\], insulin-like growth factor binding protein 7 (*IGFBP7*) \[[@B34]\], fibromodul (*FMOD*) \[[@B28]\], cathepsin S (*CTSS*) \[[@B35]\], secreted frizzled-related protein 4 (*SFRP4*) \[[@B34]\], bone marrow stromal cell antigen 1 (*BST1*) \[[@B35]\], collagen, type XI, alpha 1 (*COL11A1*) \[[@B34]\], collagen, type V, alpha 1 (*COL5A1*) \[[@B34]\], *PTGES*\[[@B36]\] and *ADAMTS5*\[[@B37]\]. These genes were expressed at significantly elevated levels in OA meniscal cells compared to normal meniscal cells (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). ADAMTS5 is a major cartilage matrix degrading enzyme and has been implicated in articular cartilage degeneration previously \[[@B38],[@B39]\]. The elevated expression of ADAMTS5 in OA meniscal cells suggests that ADAMTS5 may play a role in meniscal degeneration.

Furthermore, many genes that have been previously found to be expressed at decreased levels in other types of OA cells or tissues were also detected in this study. They are *MMP10*\[[@B34]\], *MMP12*\[[@B40]\], tenascin XB (*TNXB*) \[[@B34]\], fusion (*FUS*) \[[@B28]\], melanoma cell adhesion molecule (*MCAM*) \[[@B35]\], and T-box 5 (*TBX5*) \[[@B5]\]. These genes were expressed at decreased levels in OA meniscal cells compared to normal meniscal cells (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). The consistency between our findings and the previous findings provides strong support for our hypothesis that OA meniscal cells are different from normal meniscal cells and may play an active role in the development of OA.

Our study has some limitations which should be considered. The control meniscal cells we used were derived from the menisci of osteosarcoma patients and were not optimal normal control meniscal cells. To minimize this limitation, we only collected overtly normal-appearing meniscal and cartilage specimens (grade 0) from osteosarcoma patients whose tumors were located far away from the knee joints. In addition, we analyzed the differential gene expression using meniscal cells rather than using meniscal tissue specimens directly to eliminate the effect of different drugs that might be taken by OA and osteosarcoma patients at the time of surgery.

Most meniscal cells synthesize type I collagen as their major collagen product. The meniscal cells in the inner, central nonvascularized region of meniscus synthesize type II collagen. It is an open question at this time as to whether a single cell type exists in the meniscus that displays a fibroblast-like phenotype or a chondrocyte-like phenotype depending on its environment, or whether two or more distinct cell types exist. Therefore, it is not absolutely certain at this time whether the differences in the gene expressions detected in this study reflect the overall differences between OA meniscal cells and the control meniscal cells or only reflect the differences between a subpopulation of OA meniscal cells and a subpopulation of the control meniscal cells. Another limitation is that the age of osteosarcoma patients was younger than the age of OA patients. Therefore, certain genes we detected may be age-related rather disease-specific. It is difficult to obtain age-matched control meniscal specimens because osteosarcoma occurs often in younger patients while OA occurs mostly in older patients. We will continue this line of study when more age matched normal control meniscal specimens become available in the future. In spite of these limitations, the consistency between our findings and the previous findings that many of the genes we detected are also abnormally expressed in other OA cell types/tissues \[[@B4],[@B5],[@B23],[@B28],[@B34]-[@B36],[@B40]\] suggests that many of the differential gene expressions detected in this study are disease-specific.

Conclusions
===========

Our findings suggest that OA is not merely a cartilage disease, but also a disease of the menisci. OA meniscal cells may play an active role in the disease process of OA. Investigation of the gene expression profile of OA meniscal cells compared to normal meniscal cells may reveal new therapeutic targets for OA therapy and uncover novel disease markers for early diagnosis of OA.
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